Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

被引：18
|
作者：
Ghirardi, Arianna [1 ]
Carobbio, Alessandra [1 ]
Masciulli, Arianna [1 ]
Barbui, Tiziano [1 ]
机构：
[1] IFROM Res Fdn, Papa Giovanni Hosp 23, Bergamo, Italy
来源：
BLOOD CANCER JOURNAL | 2018年 / 8卷
关键词：
MYELOPROLIFERATIVE NEOPLASMS; RISK;
D O I：
10.1038/s41408-017-0038-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] 5-YEAR FOLLOW-UP OF PATIENTS WITH SICKLE-CELL-ANEMIA TREATED WITH HYDROXYUREA
    SIMMONSOBRIEN, E
    BLOOD, 1993, 82 (10) : A356 - A356
  • [22] Follow-up segmentation of lung tumors in PET and CT data
    Opfer, Roland
    Kabus, Sven
    Schneider, Torben
    Carlsen, Ingwer C.
    Renisch, Steffen
    Sabczynski, Joerg
    MEDICAL IMAGING 2009: COMPUTER-AIDED DIAGNOSIS, 2009, 7260
  • [23] Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy
    Thomas, Ronay
    Dulman, Robin
    Lewis, Angela
    Notarangelo, Bailey
    Yang, Elizabeth
    PEDIATRIC BLOOD & CANCER, 2019, 66 (09)
  • [24] Telomere dynamics in childhood leukemia and solid tumors: a follow-up study
    Franco, S
    Ozkaynak, MF
    Sandoval, C
    Tugal, O
    Jayabose, S
    Engelhardt, M
    Moore, MAS
    LEUKEMIA, 2003, 17 (02) : 401 - 410
  • [25] Telomere dynamics in childhood leukemia and solid tumors: a follow-up study
    S Franco
    M F Ozkaynak
    C Sandoval
    O Tugal
    S Jayabose
    M Engelhardt
    M A S Moore
    Leukemia, 2003, 17 : 401 - 410
  • [26] Follow-up Care in Cancer: selected solid Tumors and hematological Neoplasias
    Rorden, Malte
    Hinterleitner, Clemens
    Metzger, Janina
    Kanz, Lothar
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (05) : 334 - 342
  • [27] Hematologic Follow-up as Clue to Polycythemia Vera due to JAK2 Mutation Presenting as Late Onset Chorea
    Barow, Ewgenia
    Hoppe, Julia
    Mainka, Tina
    Schneider, Susanne A.
    Ganos, Christos
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2018, 5 (01): : 83 - 85
  • [28] Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera Without Splenomegaly: 156-Week Follow-Up From the Phase 3 RESPONSE-2 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 15 - 17
  • [29] Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study
    Passamonti, Francesco
    Palandri, Francesca
    Saydam, Guray
    Benevolo, Giulia
    Egyed, Miklos
    Callum, Jeannie
    Devos, Timothy
    Sivgin, Serdar
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Bensasson, Caroline
    Kandra, Albert
    Morando, Juliane
    Griesshammer, Martin
    BLOOD, 2018, 132
  • [30] ACUTE-LEUKEMIA AND MYELODYSPLASIA IN POLYCYTHEMIA-VERA - A CLINICAL-STUDY WITH LONG-TERM FOLLOW-UP
    NAJEAN, Y
    DESCHAMPS, A
    DRESCH, C
    DANIEL, MT
    RAIN, JD
    ARRAGO, JP
    CANCER, 1988, 61 (01) : 89 - 95
12345